Analyst Rating Update on Peregrine Pharmaceuticals (PPHM)

Peregrine Pharmaceuticals (PPHM) : The consensus on Peregrine Pharmaceuticals (PPHM) based on 3 analyst recommendation on the company stock is 1.67, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 2 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

Peregrine Pharmaceuticals (PPHM) : The consensus price target for Peregrine Pharmaceuticals (PPHM) is $1 for the short term with a standard deviation of $0.5. The most optimist securities analyst among the 3 who monitor the stock believes that the stock can reach $2, however, the pessimist price target for the company is $1.

For the current week, the company shares have a recommendation consensus of Buy.


Peregrine Pharmaceuticals (NASDAQ:PPHM): The stock opened at $0.36 on Wednesday but the bulls could not build on the opening and the stock topped out at $0.37 for the day. The stock traded down to $0.35 during the day, due to lack of any buying support eventually closed down at $0.35 with a loss of -1.70% for the day. The stock had closed at $0.36 on the previous day. The total traded volume was 888,277 shares.

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of monoclonal antibodies in clinical trials for the treatment and diagnosis of cancer. The Company has two platforms and is pursuing multiple clinical programs in cancer with its lead immunotherapy candidate bavituximab, its phosphatidylserine (PS) targeting agent, PGN65, and its brain cancer therapy Cotara. Bavituximab is the Companys therapeutic PS-targeting antibody. PGN650 is its PS-targeting imaging agent. The Company is evaluating the bavituximab investigator-sponsored trials (IST) in front-line, HER2-negative metastatic breast cancer, liver cancer, rectal adenocarcinoma and advanced melanoma. It is also evaluating PGN650 imaging in multiple solid tumor types. The Company`s Impavido biomanufacturing subsidiary Avid Bioservices, Inc., provides commercial and clinical manufacturing services for the Company and third-party clients.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.